Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
44
MDXH Quote, Financials, Valuation and Earnings
Last price:
$2.1900
Seasonality move
:
-21.37%
Day range:
$2.1000 - $2.1400
52-week range:
$1.5500 - $4.6400
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.81x
P/B ratio:
6.20x
Volume:
69K
Avg. volume:
168.5K
1-year change:
-44.24%
Market cap:
$105.4M
Revenue:
$70.2M
EPS (TTM):
-$1.52
Analysts' Opinion
-
Consensus RatingMDxHealth SA has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, MDxHealth SA has an estimated upside of 183.57% from its current price of $2.1300.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.1300.
Fair Value
-
According to the consensus of 4 analysts, MDxHealth SA has 183.57% upside to fair value with a price target of -- per share.
MDXH vs. S&P 500
-
Over the past 5 trading days, MDxHealth SA has underperformed the S&P 500 by -12.7% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
MDxHealth SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MDxHealth SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter MDxHealth SA reported revenues of $23.3M.
Earnings Growth
-
MDxHealth SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MDxHealth SA reported earnings per share of -$0.40.
Enterprise value:
107.5M
EV / Invested capital:
1.57x
Price / LTM sales:
0.81x
EV / EBIT:
--
EV / Revenue:
1.27x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-4.17x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$52.3M
Return On Assets:
-31.08%
Net Income Margin (TTM):
-49.52%
Return On Equity:
-650.14%
Return On Invested Capital:
-85.88%
Operating Margin:
-26.13%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $30.2M | $63.7M | $84.7M | $19.4M | $23.3M | |
| Gross Profit | $14.8M | $38.5M | $52.3M | $12.6M | $14.3M | |
| Operating Income | -$36.4M | -$30.5M | -$25.8M | -$4.6M | -$6.1M | |
| EBITDA | -$33M | -$28.7M | -$32.1M | -$2.1M | -$3.7M | |
| Diluted EPS | -$2.58 | -$2.06 | -$1.52 | -$0.37 | -$0.40 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $40.9M | $45.6M | $70.2M | |
| Total Assets | -- | -- | $122.6M | $135.7M | $157.4M | |
| Current Liabilities | -- | -- | $19.3M | $18.8M | $45.5M | |
| Total Liabilities | -- | -- | $101.1M | $117.9M | $140.4M | |
| Total Equity | -- | -- | $21.5M | $17.8M | $17M | |
| Total Debt | -- | -- | $35.3M | $36M | $51.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$23.8M | -$22.8M | -$4.3M | -$5.6M | |
| Cash From Investing | -- | -$6.3M | -$2.1M | -$439K | -$13K | |
| Cash From Financing | -- | $34.5M | $41.4M | -$2.3M | $33.6M | |
| Free Cash Flow | -- | -$30.6M | -$25.8M | -$5.1M | -$5.8M | |
MDXH
Sector
Market Cap
$105.4M
$46.1M
Price % of 52-Week High
45.91%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-40.99%
-0.6%
1-Year Price Total Return
-44.24%
-30.52%
Beta (5-Year)
-390,599.621
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.2663
200-day SMA
Sell
Level
$2.4906
Bollinger Bands (100)
Sell
Level
1.8856 - 2.7256
Chaikin Money Flow
Sell
Level
-2M
20-day SMA
Sell
Level
$2.1645
Relative Strength Index (RSI14)
Sell
Level
49.7248
ADX Line
Sell
Level
13.8276
Williams %R
Neutral
Level
-65
50-day SMA
Buy
Level
$2.0282
MACD (12, 26)
Buy
Level
0.0665
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Sell
Level
-828K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.3063)
Sell
CA Score
(Annual)
Level (-3.5959)
Buy
Beneish M-Score
(Annual)
Level (-2.8713)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (5.3952)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
Stock Forecast FAQ
In the current month, MDXH has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MDXH average analyst price target in the past 3 months is --.
-
Where Will MDxHealth SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that MDxHealth SA share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About MDxHealth SA?
Analysts are divided on their view about MDxHealth SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MDxHealth SA is a Sell and believe this share price will drop from its current level to --.
-
What Is MDxHealth SA's Price Target?
The price target for MDxHealth SA over the next 1-year time period is forecast to be -- according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MDXH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MDxHealth SA is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MDXH?
You can purchase shares of MDxHealth SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MDxHealth SA shares.
-
What Is The MDxHealth SA Share Price Today?
MDxHealth SA was last trading at $2.1900 per share. This represents the most recent stock quote for MDxHealth SA. Yesterday, MDxHealth SA closed at $2.1300 per share.
-
How To Buy MDxHealth SA Stock Online?
In order to purchase MDxHealth SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
